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was 14.10, 14.05 for LF, and 14.02 for PNF. Both LF and PNFwere dominated by CCH.
Sensitivity analysis confirmed the model was sensitive to changes in clinical effi-
cacy. Cost-effectiveness acceptability curves indicated that CCHwasmost likely to
be cost-effective across a wide range of willingness to pay, including values over
$100,000 per QALY gained. CONCLUSIONS: CCH was less expensive and was asso-
ciated with slightly more QALYs than LF and PNF for treatment of Dupuytren’s
contracture.
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OBJECTIVES: The cost of hip fractures associated with osteoporosis have become a
growing burden on the US health care system. Cost-effective treatments are
needed to prevent hip fractures in postmenopausal women with osteoporosis and
reduce the amount of resources consumed by these preventable events. The ob-
jective of this study was to develop a decision tree model to assess the cost-effec-
tiveness of four treatment options: alendronate, risedronate, ibandronate and a
“no treatment group” for the prevention of hip fractures. METHODS: A decision
tree model was developed from the third-party payer perspective using published
efficacy results from randomized controlled trials. Patients were assumed to have
osteoporosis, aged  65 years, be fully adherent and unable to change or discon-
tinue medication therapy. The incidence of hip fracture was estimated from the
literature. Medication costs were assigned from published wholesale acquisition
costs (WAC) by First DataBank. The mean cost of hip fractures and all direct costs
associated with 12-month post-fracture treatment were estimated from the liter-
ature. All costs were adjusted to 2011 dollars. RESULTS: Alendronate 70 mg once
weekly dominated the “no treatment” and the ibandronate treatments. The rise-
donrate 35 mg to alendronate 70 mg incremental cost-effectiveness ratio (ICER)
demonstrated that for every $469,553 spent one additional hip fracture would be
avoided. These results were consistent throughout the one-way sensitivity analy-
sis, which varied the cost per hip fracture and the efficacy of each medication.
When the incidence of hip fracture was assumed to be 3.57%, risedronate also
dominated the” no treatment” and ibandronate groups. CONCLUSIONS: Alendro-
nate 70mg once weekly was dominate in preventing hip fractures compared to
risedonrate, ibandronate and no treatment. The risedronate to alendronate ICER
demonstrated that the cost to avoid one hip fracture was $469,553 – typically be-
yond most payers’ willingness to pay.
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OBJECTIVES: Rheumatoid arthritis (RA) affects1.3million Americans, accounting
for 9million physician visits and250,000 hospitalizations annually. Drug therapy
is costly but essential. This study evaluates the cost-effectiveness of golimumab, a
recently approved TNF- inhibitor (TNF-I) compared with existing agents (inflix-
imab, etanercept, adalimumab), when given in combination with methotrexate
(MTX) from a third-party payer perspective.METHODS: A Markov model was con-
structed to follow a hypothetical cohort of 10,000 patients with active RA who
received one of the four TNF-I and MTX across patient life-time. The primary ef-
fectiveness outcomes were the American College of Rheumatology (ACR)-20 re-
sponse ratesmapped to health assessment questionnaire-scores to derive quality-
adjusted life-years (QALYs). ACR-20 rates were derived from a systematic review of
efficacy trials. Long-term drug withdrawal rates were derived from observational
studies. Data for drug, administration, monitoring, toxicity and RA-related direct
costs were derived from the literature. Incremental costs (2011 US$) per QALYwere
compared between TNF-Is. One-way and probabilistic sensitivity analysis (PSA)
techniques were employed to examine effects of various assumptions and param-
eter uncertainty. RESULTS: GolimumabMTX generated the highest per-person
QALYs (3.75 QALY), whereas infliximabMTX strategy generated the least QALYs
(3.57). InfliximabMTX resulted in the least direct costs of $317,455 over the pa-
tient’s life-time compared to etanerceptMTX ($324,855), adalimumabMTX
($323,503) and golimumabMTX ($324,159). The base-case incremental cost-effec-
tiveness ratios (ICERs) foretanerceptMTX, adalimuamabMTX, and
golimumabMTXcompared to infliximabMTXwere $69,211, $44,465 and $38,255/
QALY, respectively. GolimumabMTX dominated etanerceptMTX, while the
ICER for golimumabMTX vs adalimumabMTX was $16,729/QALY. In one-way
sensitivity analyses, these results were robust to a range of assumptions except for
dosing of infliximab and long-term withdrawal rates. In the PSA, the probability of
golimumab being cost-effective at the commonly accepted $50,000/QALY thresh-
old was 0.29. CONCLUSIONS: Golimumab appears to be a cost-effective treatment
option for RA compared to existing TNF-Is.
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OBJECTIVES: Nonsteroidal antiinflammatory drugs (NSAIDs) plus a proton pump
inhibitor (PPI) are in widespread use for rheumatic diseases in Algeria, but can
cause peptic ulcers and gastrointestinal bleeding and perforation. The National
Institute for Health and Clinical Excellence (NICE) health economic model for as-
sessing the cost-effectiveness of celecoxib compared to multiple NSAIDSPPI in
the treatment of osteoarthritis has been updated using new adverse event (AE)
risks from the CONDOR trial. In light of this new information, this study aimed to
evaluate the incremental cost-effectiveness ratio (ICER) of celecoxib compared to
different NSAIDS PPI. METHODS: The NICE model was adapted for this study to
update the relative risks of adverse events; using data from the CONDOR trial for
patients above 65yrs. Patients could initiate treatment with celecoxib, NSAIDs (di-
clofenac, naproxen, ibuprofen) plus omeprazole. Conditional probabilities of the
model were obtained from published clinical trials and effectiveness measure was
the Quality-Adjusted life years gained (QALY). The analysis was conducted from
the healthcare payer’s perspective. Resource use and costs were obtained from
official Algerian databases. Probabilistic sensitivity analysis (PSA) was performed
and acceptability curves were constructed. RESULTS: Celecoxib showed on the
six-months period lower expected costs per patient (US$422.84) compared to
naproxenPPI (US$445.79) and ibuprofenPPI (US$775.11). The lowest expected
costs resulted for diclofenacPPI (US$257.10). On the other hand, celecoxib was
associated with higher effectiveness (0.398 QALYs), followed by ibuprofenPPI
(0.393 QALYs) and naproxenPPI (0.392 QALYs). Likewise, celecoxib has an ICER of
US$343.81 per QALY compared to diclofenac which is below 1 GDP per capita for
Algeria (US$7,300). Acceptability curves showed the same results with a mean of
65.5% of certainty. CONCLUSIONS: (DISCUSSION): The results suggest that when
new AE risks are used, celecoxib remains a cost-effective treatment for OA when
compared to diclofenac plus a PPI and cost-saving when compared to
naproxenPPI or ibuprofenPPI.
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OBJECTIVES: Osteoarthritis is a major cause of musculoskeletal pain and inability
to work. Evidence shows that clinical improvement after viscosupplementation
(VS) is able to delaying the average time until total knee arthroplasty (TKA) indica-
tion. This study aimed to conduct cost-effectiveness and budget impact analysis
(BIA) of viscosupplementation with Orthovisc™ (Hyaluronan) versus conservative
treatment in Kellgren & Lawrence(K&L) grades II and III knee osteoarthritis (KOA)
from the Brazilian private health care system perspective. METHODS: A 3-year
time horizon Markov simulation model was developed to project costs and out-
comes associated to KOA progression. Patients could start in ‘Orthovisc™ Treat-
ment’ (conservative treatment  Orthovisc™) or ‘Conservative Treatment’ states
and then transit (6-month cycle duration) in states ‘TKA’, ‘Post-operative’ and
‘Death’ according to transition probabilities extracted from systematic review.
Only direct medical costs were considered and collected from Brazilian private
official databases. Outcome was expressed as ‘avoided TKA procedure’. BIA was
developed for a hypothetical private health insurance cohort of 10,000 patients
over 50 years. Univariate sensitivity analyseswere performed formain parameters.
A 5% annual discount rate was applied for costs and benefits. RESULTS: For a
hypothetical 1000 patient’s cohort in a 3-year time horizon, 34TKAwere performed
in Orthovisc™ group versus 164TKA in conservative treatment group, avoiding 130
TKA procedures. Total costs per group were 17,367,259BRL and 17,494,500BRL for
Orthovisc™ and conservative treatment groups, respectively, with an incremental
cost of -127,241BRL. Sensitivity analysis showed cost-saving results for years 2 and
3. BIA showed savings of 180,401BRL for the private health insurance and 99TKA
avoided in a 3-year time horizon. CONCLUSIONS: Viscosupplementation treat-
ment, based on a Markov simulation model using Orthovisc™ data, in K&L grades
II and III KOA showed to be cost-saving regarding avoided TKA in a 3-year time
horizon over conservative treatment at Brazilian private health care system, lead-
ing to reduction in costs and surgical procedures.
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OBJECTIVES: Refractory Chronic Gout (RCG) affects approximately 4% of patients
with gout. It is characterized by failure to achieve normal serum uric acid levels or
adequately control gout signs and symptoms with xanthine oxidase inhibitors at
the maximum medically appropriate dose, or by contraindication to the use of
these drugs. Pegloticase was recently launched in the US for treatment of RCG.
METHODS: We developed a two-part sequential model: 1) the first 6 months rep-
resented as a decision tree; and 2) the remaining years as separate empirical fore-
casts. We modeled the severity of RCG as a combination of flares/year and tophi
status. We used data from two replicate, randomized, double-blind, placebo-con-
trolled trials (C0405 and C0406), which were conducted between June 2006 and
October 2007 in 56 rheumatology practices. The comparator group is placebo. To
model disease progression, we employed a vector autoregression methodology to
approximate Markov Chain transition probabilities. We estimated utility regres-
sions fromNHWSanduse a blended cost of $2600/vial. RESULTS: For a 20-year time
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horizon model with 6-months of treatments every 5-years (3% discount rates for
cost and utilities), the projected incremental cost-effectiveness ratios (ICERS) for
3-5 flaresNo Tophi and6 flaresNo Tophi were $60,000K and $2,000K, respec-
tively. For the remaining gout states of RCG (3-5 flares  Tophi and 6 flares 
Tophi), pegloticase strictly dominates the placebo, producing better outcomes at
lower cost. Weighting these gout groups by their relative prevalence, the popula-
tion mean ICER shows pegloticase as dominant versus placebo. Given the initial
cost of therapy, the ICER varies depending on the timeframe: for: 3, 5, and 10-years,
the population ICERs are $68,000, $47,000, and $5,000, respectively. CONCLUSIONS:
Pegloticase is projected to be cost-effective compared to placebo treatment for
treating patients with RCG. The ICERs compare favorably with many technologies
in widespread use.
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OBJECTIVES: To identify which is the alternative that minimizes costs in the treat-
ment of Rheumatoid Arthritis with biological therapy in Mexico.METHODS: A cost
minimization evaluation was done, comparing alternatives considered compara-
ble in effectiveness in the management of RA in adult patients (Infliximab, Etaner-
cept and Adalimumab, Rituximab, Tocilizumab) in a 9-year horizon. Since the fre-
quency of retreatment with Rituximab hasn=t been standarized, the assumption of
the retreatment scheme of every 9 months as the average of the standards was
taken in account. Costs are expressed in US dollars. RESULTS: The total cost for 9
years with Rituximab was the lowest ($ 74,040), followed by Tocilizumab ($ 75,328),
Etanercept ($ 76,034), Adalimumab ($ 89,490) and Infliximab ($ 91,543), generating
savings with Rituximab of $ 1,288, $ 1,994, $ 15,450 and $ 17,503 respectively. Like-
wise, Rituximab was the alternative with the lowest number of applications (26),
compared with Tocilizumab (117), Etanercept (468), infliximab (60) and Adali-
mumab (234). In the budget impact analysis, assuming that 100%of the patients are
treated with Rituximab, the health facility could generate savings and therefore
could gain access to biological therapy to more patients tan if they were treated
under a scheme without Rituximab. The results of the sensitivity analysis, taking
as a variable number of applications of Rituximab year showed, with an 85.44% of
probability, that rituximab is shown to be the least costly alternative compared
with Infliximab; 74.09% compared with Adalimumab; 53.17% compared with Etan-
ercept, and with 51.38%, Rituximab is also less expensive compared to
Tocilizumab. CONCLUSIONS: Rituximab proved to be an alternative that mini-
mizes costs, generating savings and allowing greater access to therapy for patients
with RA, offering benefits to health institutions, not only improving the quality of
care with an innovative therapy, but also allowing significant cost savings.
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OBJECTIVES: To demonstrate the effect of ankylosing spondylitis (AS) on sick leave
and estimate the productivity loss due to the absenteeism. METHODS: Patients
diagnosed with AS who attended to tertiary-care outpatient rheumatology clinics
consecutivelywere evaluated for demographics, disease characteristics, treatment
regimens, WLQ, HAQ, BASDAI, and BASFI. Productivity loss, was calculated based
on the interim analysis results of this ongoing observational study. Data on total
days of sick leave in the last three months was used for the estimation of one-year
absenteeism. Additionally, the relationship between the sick leave and BASFI
scores was evaluated. RESULTS: Results from a total of 402 AS patients were ana-
lyzed. Among 220 patients (180 male (82 %); mean age 36.4 years; mean disease
duration 7.7 years) in paid employment, 56.4 % had sick leave over a period of 3
months and the mean duration of sick leave they reported on average was 8 days
(95% CI: 5.2-10.8). This duration was extrapolated to a total of 32 days per year.
Based on the national statistics, the average daily productivity loss for Turkey is
91.7 TL (calculated by dividing the average monthly productivity loss by 20). The
annual productivity loss was calculated as 2934.4 TL (1198 €) per patient due sick
leave caused byAS. Besides, 40.7%of these patientswho reported sick leave needed
to get support from their relatives or friends for their daily routine activities. The
mean BASFI score was 27.88 for patients who reported sick leave, while it was 22.3
for patients who did not and the difference is statistically significant.
CONCLUSIONS: Annual productivity loss due to sick leave caused by AS is 1198 €
per patient and there is a statistically significant difference between the BASFI
scores of those patients who had sick leave and those who did not.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: This study reports dosing and refill compliance patterns observed in
golimumab (GLM) -treated rheumatoid arthritis (RA) patients.METHODS: A retro-
spective study was conducted of adult RA patients with 2 GLM prescriptions
between April 24, 2009 and December 31, 2010;  1 RA diagnosis during the study
period; continuous activity in the Source® LX database (6months pre;6months
post index prescription) and a 28-31 day GLM supply. Refill compliancewas defined
as occurring  1 week of the expected 28-31 day (d) interval. The percent of com-
pliant GLM refill intervals and the percent of patients with refill compliance at the
6th GLM dose were assessed. Descriptive statistics were used to characterize the
study population. RESULTS: A total of 1103 RA patients and 6432 GLM refill inter-
vals were observed. The sample was 82% female; mean age of 53 years with 63%
bio-experienced. A 50 mg GLM dose was found in 98% of all fills. Mean  SD refill
interval was 35.722.0 d; median was 31 d. Refill intervals were 35.421.3 d in
bio-experienced patients and 36.323.0 d in bio-naïve patients; medianwas 31 d in
both subgroups. Refill compliance was observed in 80% of all intervals. Refill com-
pliance at the 6th GLM dose was achieved by 84% of patients overall.
CONCLUSIONS: In this retrospective analysis of an administrative claims data-
base, 98% of GLM doses were 50 mg with approximately once monthly refill inter-
vals. Refill compliance was observed in 80% of all GLM refills and in greater than
80% of RA patients at the sixth GLM dose. Median refill interval and refill compli-
ance appeared similar in bio-experienced and bio-naïve subgroups. Further study
of these trends using additional data sources are desired to substantiate these
preliminary findings.
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OBJECTIVES: The study objectives were to compare long term medication adher-
ence among first time adalimumab and etanercept users over a three-year follow
up period, and to identify factors that were associated with high medication
adherence.METHODS: A total of 1672 adult ( 18 years) rheumatoid arthritis (RA)
patients who were first time adalimumab (N382) or etanercept (N1290) users
between January 1, 2003 andDecember 31, 2007 in the Kaiser Permanente Southern
California (KPSC) Health Planwere included. Subjectswere required to have at least
two RA diagnosis records and disease-modifying anti-rheumatic drugs (DMARDs)
usewithin one year after the first diagnosis. Continuous enrollment one year prior,
and three years after the initiation (index date) of adalimumab and etanercept
treatment was required. First time users were defined as subjects who did not use
adalimumab or etanercept in the 12-month period prior to index date. Medication
adherence was measured through proportion days covered (PDC). Association of
long term high adherence with age, gender, race, insurance type, comorbidity and
history of oral DMARDs were estimated using Poisson regression with robust stan-
dard errors. RESULTS: The mean age, gender and race distribution were 52.5 years
old, 80.4% female, and 34.0% non-whites in adalimumab group; 53.3 years old,
77.9% female, and 36.2% non-whites in etanercept group. The adherence rate in
one-year, two-year and three-year follow up in adalimumab group was 0.63, 0.52
and 0.46, and in etanercept group was 0.69, 0.59 and 0.53. The incidence rate ratio
(IRR) of adalimumab was 0.78 (95% CI: 0.68 -0.90), 0.73 (95% CI: 0.61-0.88), and 0.70
(95% CI: 0.56-0.87) in one-year, two-year and three-year follow up respectively. Age
and history of oral DMARDs were significantly associated with adherence.
CONCLUSIONS: This study highlighted a relatively lower long term adherence rate
in adalimumab users as compared to etanercept users in adult RA patients within
KPSC.
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OBJECTIVES: Themain objective of this study was to assess themedication adher-
ence among individuals with rheumatoid arthritis (RA) enrolled in a stateMedicaid
fee-for-service (FFS) program. Factors influencing medication adherence were
identified. Lastly, the role of adherence in influencing the utilization of acute care
services (hospitalization/emergency room visit) was ascertained. METHODS: The
target population included nonelderly adult recipients (21-64 years) whowere con-
tinuously enrolled in the Mississippi Medicaid FFS program from January 1, 2006 to
December 31, 2007. Recipients who had a medical services claim with a primary or
secondary diagnosis of RA in calendar year 2006were identified. Medication adher-
ence (measured as proportion of days covered (PDC)) was determined using calen-
dar year 2007 data. Recipients with adherence (PDC) 80% were classified as ad-
herent. Logistic regression analyses were used to determine factors predicting
medication adherence and the effect of adherence on acute care services
utilization. RESULTS: Roughly 20% of recipients with RA were adherent. Older age
(odds ratio (OR) 1.031; p0.005), white race (OR 1.684; p0.005), and lower Charl-
son comorbidity index (CCI) score (OR 0.785; p0.005) were significant predictors
of adherence. Adherence did not have a significant association with acute care
services utilization after controlling for demographic and disease-related
covariates. CONCLUSIONS: Only one in five Medicaid recipients with RA were
found to be adherent. Lower levels of adherence among individuals with RA could
contribute to poor outcomes in these individuals over time. Policy makers should
undertake intervention programs aimed at increasing medication adherence in
this underprivileged population.
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